No annual revenue total was found in CONTEXT THERAPEUTICS INC.'s SEC filings.
Context Therapeutics Inc. (CNTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$26.4 million. As of Jun 30, 2026 it held $43.0 million in cash and investments and $200,000 in total debt.
Revenue
—
Net income (TTM)
$-45.96M
-34.3% vs year-ago TTM
Operating cash flow (TTM)
$-33.97M
-91.9% vs year-ago TTM
Free cash flow (TTM)
$-34.03M
EPS (TTM)
$-0.48
-24.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
91.88M
+2.4% vs prior year
Net cash
$42.79M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Philadelphia, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1842952
- Former names
- Context Therapeutics LLC (until May 3, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$39.7M | -$29.9M | -$25.1M | -$15.4M | -$10.5M |
| Net income | -$36.1M | -$26.7M | -$24.0M | -$14.8M | -$10.5M |
| Diluted EPS | -$0.38 | -$0.46 | -$1.50 | -$0.93 | -$3.69 |
| Operating cash flow | -$26.4M | -$14.6M | -$21.0M | -$13.5M | -$8.8M |
| Free cash flow | -$26.4M | -$14.6M | -$21.0M | -$13.6M | — |
| Total assets | $68.5M | $98.1M | $16.1M | $38.0M | $51.3M |
| Total liabilities | $8.0M | $2.9M | $4.2M | $3.2M | $3.0M |
| Stockholders' equity | $60.5M | $95.3M | $11.9M | $34.8M | $48.3M |
| Cash and investments | $66.0M | $94.4M | $14.4M | $35.5M | $49.6M |
| Total debt | $100,000 | $200,000 | $0 | $55,000 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Aug 5, 2026 | Aug 5, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 31, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 26, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 15, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
May 18, 2026 | May 14, 2026 |
All 307 Context Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.